RayKnowChina Research Map
Shortlist

Wuhu

First Affiliated Hospital of Wannan Medical College

皖南医科大学第一附属医院

Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Wannan Medical College

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  2. Hepatocellular carcinoma肝细胞癌22 papers led
  3. Stomach cancer胃癌30 papers led
  4. Hepatoblastoma肝母细胞瘤2 papers led
  5. Osteosarcoma骨肉瘤3 papers led
  6. Neuroblastoma神经母细胞瘤1 paper led
  7. Ewing sarcoma尤文肉瘤0 papers led
  8. Multiple myeloma多发性骨髓瘤0 papers led
  9. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  10. Haemophilia A血友病 A1 paper led
  11. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  12. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  13. Behçet disease白塞病1 paper led
  14. IgA nephropathyIgA 肾病1 paper led

Not listed for: Nasopharyngeal carcinoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

1 hospital in Wuhu for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 22 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 5520222023: 3320232024: 3320242025: 992025

1 hospital in Wuhu for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisHepatitis B & cirrhosisImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led22
  1. Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma.2025Balkan medical journalFree full text
  2. GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway.2025Biochemical genetics
  3. Emerging importance of m6A modification in liver cancer and its potential therapeutic role.2025Biochimica et biophysica acta. Reviews on cancer
  4. Viral-Track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma.2025Communications biologyFree full text
  5. Ciclopirox, a broad-spectrum antifungal drug, moonlights as a pyroptosis agonist to drive hepatocellular carcinoma cell death.2025European journal of pharmacology
  6. Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin B1-induced hepatocellular carcinoma.2025International journal of surgery (London, England)
  7. CYP8B1 is a prognostic biomarker with important functional implications in hepatocellular carcinoma.2025Oncology reportsFree full text
  8. Heparanase and MMP-9 synergistically induce endothelial-mesenchymal transition in portal vein microvessels to promote hepatocellular carcinoma metastasis.2025Pathology, research and practice
  9. Targeting DUSP3 promotes cell senescence by activating the notch1 pathway to treat hepatocellular carcinoma.2025Tissue & cell
  10. CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma.2024Experimental biology and medicine (Maywood, N.J.)Free full text
  11. Glycosyltransferase B4GALNT1 promotes immunosuppression in hepatocellular carcinoma via the HES4-SPP1-TAM/Th2 axis.2024Molecular biomedicineFree full text
  12. LINC00665 target let-7i/HMGA1 promotes the proliferation and invasion of hepatoma cells.2024Mutation research
  13. Association of APC Expression with Its Promoter Methylation Status and the Prognosis of Hepatocellular Carcinoma.2023Asian Pacific journal of cancer prevention : APJCPFree full text
  14. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.2023PeerJFree full text
  15. Different Approaches of Laparoscopic Mesohepatectomy for Centrally Located Hepatocellular Carcinomas.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  16. m1A methylation modification patterns and metabolic characteristics in hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  17. ncRNA-Regulated LAYN Serves as a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma: A Bioinformatics Analysis.2022BioMed research internationalFree full text
  18. Adiponectin and the risk of gastrointestinal cancers in East Asians: Mendelian randomization analysis.2022Cancer medicineFree full text
  19. Hepatitis B virus PreS2 mutants in liver cancer patients.2022Cellular and molecular biology (Noisy-le-Grand, France)
  20. LncRNA SLC16A1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-411/MITD1 axis.2022Journal of clinical laboratory analysisFree full text
  21. CCT4 suppression inhibits tumor growth in hepatocellular carcinoma by interacting with Cdc20.2021Chinese medical journalFree full text
  22. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?2021Gut and liverFree full text
Chinese-language papers (not in the count)1
  1. [TMEM64 is highly expressed in hepatocellular carcinoma and promotes tumor cell proliferation and invasion].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 30 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
30
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 111120222023: 8820232024: 4420242025: 332025

1 hospital in Wuhu for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Registry
    NCT06126406

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu

  2. Recruiting
    S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03941561

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryNutrition & recoveryPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)NeurosurgeryRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led30
  1. Treating a single tumor deposits as two lymph node metastases can improve the accuracy of gastric cancer prognosis assessment.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. NAT10-Mediated N4-Acetylcytidine Modification of GRB7 Promotes the Progression of Gastric Cancer.2025Critical reviews in eukaryotic gene expression
  3. Tumor deposits in gastric cancer cannot be regarded as metastatic lymph nodes: A single-center retrospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. A rare early gastric mixed neuroendocrine-non-neuroendocrine neoplasm misdiagnosed as early gastric cancer.2025Revista espanola de enfermedades digestivas
  5. Nomogram Based on Body Composition and Prognostic Nutritional Index Predicts Survival After Curative Resection of Gastric Cancer.2024Academic radiology
  6. Gastric synovial sarcoma: A case report.2024Asian journal of surgery
  7. Targeting SOX13 inhibits assembly of respiratory chain supercomplexes to overcome ferroptosis resistance in gastric cancer.2024Nature communicationsFree full text
  8. Construction and validation of a prognostic model for gastric cancer patients with tumor deposits.2024PeerJFree full text
  9. A novel, safe and feasible gastrojejunal anastomosis after laparoscopic-assisted distal gastrectomy for gastric cancer: Pants-shaped anastomosis (with video).2023Asian journal of surgery
  10. A novel, safe and feasible esophagojejunal anastomosis for total gastrectomy: Pants-shaped anastomosis (with video).2023Asian journal of surgery
  11. Serum CA724 has no diagnostic value for gastrointestinal tumors.2023Clinical and experimental medicineFree full text
  12. Development and validation of a predictive model associated with lymph node metastasis of gastric signet ring carcinoma patients.2023MedicineFree full text
  13. Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT-mTOR pathway.2023Molecular carcinogenesis
  14. Clinicopathological characteristics and its association with digestive system tumors of 1111 patients with Schistosomiasis japonica.2023Scientific reportsFree full text
  15. Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer.2023Scientific reportsFree full text
  16. SOV sensitizes gastric cancer cells to radiation by suppressing radiation-induced autophagy in vitro and in vivo.2023Tissue & cell
  17. The clinical effectiveness of establishing a proximal jejunum pouch after laparoscopic total gastrectomy: A propensity score-based analysis.2022Asian journal of surgery
  18. Laparoscopic enucleation for gastric leiomyoma in the antrum (with video).2022Asian journal of surgery
  19. Clinical applicability of a new scoring system for population-based screening and risk factors of gastric cancer in the Wannan region.2022BMC gastroenterologyFree full text
  20. GGT5 Is an Independent Prognostic Biomarker in Stomach Adenocarcinoma.2022Canadian journal of gastroenterology & hepatologyFree full text
  21. Adiponectin and the risk of gastrointestinal cancers in East Asians: Mendelian randomization analysis.2022Cancer medicineFree full text
  22. M6 A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1.2022Cancer scienceFree full text
  23. TULP3 silencing suppresses cell proliferation, migration and invasion in gastric cancer via the PTEN/Akt/Snail pathway.2022Cancer treatment and research communications
  24. Clinical Study on the Evaluation of the Condition of Patients with Gastric Tumors and the Choice of Surgical Treatment by Gastric Ultrasonic Filling Method.2022Contrast media & molecular imagingFree full text
  25. Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer.2022Free radical biology & medicine
  26. Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer.2022Journal of advanced researchFree full text
  27. Clinical characteristics and risk factors for upgraded pathology in patients with gastric intraepithelial neoplasia after endoscopic submucosal dissection.2022Revista espanola de enfermedades digestivas
  28. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer.2021Journal for immunotherapy of cancerFree full text
  29. Absent in melanoma 2 suppresses gastric cancer cell proliferation and migration via inactivation of AKT signaling pathway.2021Scientific reportsFree full text
  30. Spontaneous acute epidural hematoma associated with chronic subdural hematoma due to dural metastasis of gastric carcinoma: a case report and literature review.2021The International journal of neuroscience
Chinese-language papers (not in the count)2
  1. [LncRNA LINC00342 regulates gastric cancer cell proliferation, migration and invasion by targeting miR-596].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Profilin 2 is highly expressed in gastric cancer and promotes tumor cell proliferation and migration].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06126406Study sitePhase 1Start 2023-11
  2. S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)RecruitingNCT03941561Study sitePhase 3Start 2019-01
  3. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Study sitePhase 1/Phase 2Start 2022-04
  4. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  5. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable FactorStatus unknownNCT03399253Study sitePhase 2/Phase 3Start 2017-12
  6. Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.WithdrawnNCT02736552Study sitePhase 3Start 2016-03
  7. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Study siteN/AStart 2016-03

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 2 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Wuhu for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

2 hospitals in Wuhu for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led3
  1. A prognostic model of platinum resistance in osteosarcoma: Key roles of BNIP3, MYC, and ACTA2.2025Computers in biology and medicine
  2. PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.2025PloS one
  3. GNAS, not a Highly Mutated Gene, Has Prognostic Significance and Carcinogenic Effects in Osteosarcoma.2024Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
Earlier papers (2016–2020)1
  1. A rare entity of Primary Ewing sarcoma in kidney.2020BMC surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Wuhu for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuhu for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. A rare entity of Primary Ewing sarcoma in kidney.2020BMC surgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Wuhu for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

1 hospital in Wuhu for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led2
  1. Successful Management of Severe Refractory ARDS in Hemophagocytic Lymphohistiocytosis with VV-ECMO: A Case Report and Analysis.2025The American journal of case reportsFree full text
  2. PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: A cautionary case report.2023Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Chinese-language papers (not in the count)2
  1. [Clinical Characteristics of Aggressive NK-Cell Leukemia].2023Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Characteristics for Cutaneous Involvement in Diffuse Large B-Cell Lymphoma and Hemophagocytic Syndrome patients with First Presentation of Dermatomyositis].2021Zhongguo shi yan xue ye xue za zhi
More papers found outside PubMed (not counted)1
  1. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)article

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Wuhu for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuhu for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.2020Journal of cellular and molecular medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuhu for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Wuhu for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Wuhu for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Correlation of Serum Bilirubin with Clinical and Pathological Characteristics of Patients with IgA Nephropathy.2024Archivos espanoles de urologia
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

皖南医科大学第一附属医院

First Affiliated Hospital of Wannan Medical College

芜湖

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Wǎnnán yīxué yuàn fùshǔ yì jī shān yīyuàn; Yijishan Hospital

Suggest a correctionDownload the data